Pacer BioThreat Strategy ETF
VIRS
VIRS was delisted on the 10th of October, 2024.
3 hedge funds and large institutions have $1.47M invested in Pacer BioThreat Strategy ETF in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
32% more capital invested
Capital invested by funds: $1.12M → $1.47M (+$354K)
25% less funds holding
Funds holding: 4 → 3 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$253K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$17.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Osaic Holdings
Scottsdale,
Arizona
|
-$2.86K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$234 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Royal Bank of Canada
Toronto,
Ontario, Canada
| $554K | +$253K | +8,500 | +92% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $527K | +$17.5K | +586 | +4% |
|
|
3
Osaic Holdings
Scottsdale,
Arizona
| $390K | -$2.86K | -96 | -0.8% |
|
|
4
UBS Group
Zurich,
Switzerland
| – | -$234 | -8 | Closed |
|
VIRS Hedge Fund Activity: Q2 2023 in Review
3 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Pacer BioThreat Strategy ETF (VIRS) for Q2 2023, worth a combined $1.47M — up 32% from $1.12M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of VIRS and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was Royal Bank of Canada, adding an estimated $253K. The largest seller was Osaic Holdings, cutting an estimated $2.86K.
- 3 institutional investors held Pacer BioThreat Strategy ETF (VIRS) as of Q2 2023, down from 4 in Q1 2023.
- Funds reported $1.47M of Pacer BioThreat Strategy ETF stock for Q2 2023, up 32% quarter-over-quarter.
- 0 funds opened new Pacer BioThreat Strategy ETF positions in Q2 2023 and 1 closed out, a net change of -1 holder.
- The largest Pacer BioThreat Strategy ETF buyer in Q2 2023 was Royal Bank of Canada, an estimated $253K added.
- The largest Pacer BioThreat Strategy ETF seller in Q2 2023 was Osaic Holdings, an estimated $2.86K sold.
Based on aggregated 13F filings for Q2 2023.